MammaPrint breast cancer test moving from microarray to RNA-Seq

June 6, 2017 Leave a comment 5,331 Views

Agilent Technologies Inc. (NYSE: A) and Agendia, Inc. today jointly announced an agreement to expand their relationship to include the development of an RNA-Seq kit version of Agendia’s currently marketed MammaPrint and BluePrint tests. Agendia’s MammaPrint test provides High-Risk or ...

RNA-Seq Blog Transcriptome Research & Industry News

Tag Archives: Agendia

MammaPrint breast cancer test moving from microarray to RNA-Seq

Optimised RNA extraction method unlocks tough tissues for aquaculture research

dsRID – in silico identification of dsRNA regions using long-read RNA-seq data

FUN-PROSE – predicting the response of fungal genes

Unraveling the timeline of gene expression – a pseudotemporal trajectory analysis of single-cell RNA sequencing data

INVADEseq – cataloging bacterial diversity within tumor samples

RNA sequencing identifies genetic effects of traumatic brain injury using an artificial brain

Researchers develop new method to identify and remove background noise from single cell data